Novo Nordisk (NYSE: NVO) reported Q3 EPS of DKK6.12. Revenue for the quarter came in at DKK71.31 billion.

OUTLOOK

For the 2024 outlook, sales growth is now expected to be 23-27% at CER, and operating profit growth is now expected to be 21-27% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for sales and 2 percentage points lower for operating profit

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.